Novartis AG Files Q1 2024 Financial Reports
Ticker: NVSEF · Form: 6-K · Filed: Apr 23, 2024 · CIK: 1114448
| Field | Detail |
|---|---|
| Company | Novartis Ag (NVSEF) |
| Form Type | 6-K |
| Filed Date | Apr 23, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-report, quarterly-results
TL;DR
Novartis dropped its Q1 2024 financials, check the 6-K for the deets.
AI Summary
Novartis AG filed a Form 6-K on April 23, 2024, reporting on its Q1 2024 financial results. The filing includes a Financial Report for Q1 2024 and an Interim Financial Report. Novartis AG is incorporated in Switzerland and its fiscal year ends on December 31.
Why It Matters
This filing provides investors with the latest financial performance data for Novartis AG, crucial for understanding the company's current health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not contain new or unusual risk factors.
Key Players & Entities
- Novartis AG (company) — Registrant
- April 23, 2024 (date) — Filing date
- Q1 2024 (period) — Financial reporting period
- Switzerland (location) — Country of incorporation
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to report on Novartis AG's Q1 2024 financial results, including a Financial Report for Q1 2024 and an Interim Financial Report.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed with the SEC on April 23, 2024.
What are the included exhibits in this filing?
The included exhibits are 99.1 Financial Report Q1 2024 and 99.2 Interim Financial Report.
Does Novartis AG file an annual report under Form 20-F?
Yes, Novartis AG indicates it files its annual reports under cover of Form 20-F.
What is the principal executive office address for Novartis AG?
The principal executive office address for Novartis AG is Lichtstrasse 35, 4056 Basel, Switzerland.
Filing Stats: 182 words · 1 min read · ~1 pages · Grade level 13.1 · Accepted 2024-04-23 06:06:36
Filing Documents
- a240423-6k.htm (6-K) — 15KB
- a240423-99_1.htm (EX-99) — 196KB
- a240423-99_2.htm (EX-99) — 914KB
- letterheadpr.jpg (GRAPHIC) — 25KB
- logorm.jpg (GRAPHIC) — 29KB
- coverifr.jpg (GRAPHIC) — 116KB
- 0001370368-24-000017.txt ( ) — 1349KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Novartis AG Date: April 23, 2024 By: /s/ PAUL PENEPENT Name: Paul Penepent Title: Head Financial Reporting and Accounting